30 November 2012
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Total Voting Rights
Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the recent exercise of options, the Company's share capital consists of 418,161,314 Ordinary 0.1p shares with voting rights attached (one vote per Ordinary share). The Company has no shares in Treasury therefore the total number of voting rights in Allergy Therapeutics is 418,161,314.
The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Allergy Therapeutics under the FSA's Disclosure and Transparency Rules.
For further information
Allergy Therapeutics |
+44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer |
|
Ian Postlethwaite, Finance Director |
|
|
|
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
Juliet Thompson / Clare Terlouw |
|
|
|
FTI Consulting |
+44 (0) 207 831 3113 |
Simon Conway / Susan Stuart / Victoria Foster Mitchell |
|